Personalized medicine: importance of clinical interpretative skills for real-world patient care

被引:0
|
作者
Gryn, Steven E. [1 ]
Kim, Richard B. [1 ]
机构
[1] Univ Western Ontario, Div Clin Pharmacol, Dept Med, London Hlth Sci Centre UH, London, ON N6A 5A5, Canada
基金
加拿大健康研究院;
关键词
azathioprine; clinical pharmacology; clopidogrel; metoprolol; pharmacogenetics; pharmacogenomics; statin; warfarin; IMPLEMENTATION CONSORTIUM GUIDELINES; PERCUTANEOUS CORONARY INTERVENTION; CYP2C19; GENOTYPE; BREAST-CANCER; COST-EFFECTIVENESS; ACTIVE METABOLITE; CYP2D6; CARDIOVASCULAR OUTCOMES; ANTIPLATELET THERAPY; PLATELET REACTIVITY;
D O I
10.2217/PME.14.16
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sequencing of the human genome led to great hopes and expectations for a 'genomics revolution' where disease diagnosis as well as therapies would be based on an individual's genetic makeup. Although significant progress has been made, a number of challenging hurdles must be overcome prior to the broader adoption and implementation of pharmacogenomics and personalized medicine as a part of standard patient care. One aspect of pharmacogenomics-based personalized medicine that has not garnered as much attention, a key focus of this perspective, is the importance of interpreting pharmacogenomic test results in a patient-specific clinical context, and expert physicians and other allied health care providers with the requisite expertise in clinical pharmacology and genomics who are able to provide such services.
引用
收藏
页码:395 / 408
页数:14
相关论文
共 50 条
  • [1] Personalized medicine policy challenges: measuring clinical utility at point of care
    van Rooij, Tibor
    Wilson, Donna M.
    Marsh, Sharon
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (03) : 289 - 295
  • [2] Innovation at the Intersection of Clinical Trials and Real-World Data Science to Advance Patient Care
    Swift, Brandon
    Jain, Lokesh
    White, Craig
    Chandrasekaran, Vasu
    Bhandari, Aman
    Hughes, Dyfrig A.
    Jadhav, Pravin R.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2018, 11 (05): : 450 - 460
  • [3] The Evolution of Evidence-Based Medicine: When the Magic of the Randomized Clinical Trial Meets Real-World Data
    You, Seng Chan
    Krumholz, Harlan M.
    CIRCULATION, 2022, 145 (02) : 107 - 109
  • [4] Assessing Patient Readiness for the Clinical Adoption of Personalized Medicine
    Issa, A. M.
    Tufail, W.
    Hutchinson, J.
    Tenorio, J.
    Baliga, M. Poonam
    PUBLIC HEALTH GENOMICS, 2009, 12 (03) : 163 - 169
  • [5] PARC report: health outcomes and value of personalized medicine interventions: impact on patient care
    Mitropoulou, Christina
    Litinski, Veronika
    Kabakchiev, Boyko
    Rogers, Sara
    Patrinos, George P.
    PHARMACOGENOMICS, 2020, 21 (11) : 797 - 807
  • [6] ST-segment-elevation myocardial infarction: Guidelines and the challenge of real-world patient care
    Spinler, Sarah A.
    PHARMACOTHERAPY, 2006, 26 (08): : 115S - 122S
  • [7] From clinical development to real-world outcomes with inclisiran
    Connolly, Derek L.
    Sharma, Vinoda
    Ray, Kausik K.
    CURRENT OPINION IN LIPIDOLOGY, 2024, 35 (06) : 281 - 289
  • [8] Real-world incidence of patient-reported dyspnoea with ticagrelor
    Prosser, Adaire E.
    Dawson, Jessica L.
    Koo, KethLyn
    O'Kane, Karen M.
    Ward, Michael B.
    Woodman, Richard J.
    Mangoni, Arduino A.
    Phillips, Cameron J.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2018, 9 (10) : 577 - 584
  • [9] Individualized diabetes care: Lessons from the real-world experience
    Khor, Xiao Ying
    Pappachan, Joseph M.
    Jeeyavudeen, Mohammad Sadiq
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (13) : 2890 - 2902
  • [10] Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice
    Monreal, Manuel
    THROMBOSIS AND HAEMOSTASIS, 2018, 118 (11) : 1850 - 1851